- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04383314
Targeting Hyaluronan Accumulation Through Exercise in T2DM
February 6, 2024 updated by: NYU Langone Health
A Longitudinal, Single-center Study Investigating the Effects of Exercise on Hyaluronan Accumulation in Skeletal Muscle in Individuals With Type 2 Diabetes Mellitus
A pilot longitudinal study to examine hyaluronan (HA) accumulation in muscles of individuals with Type 2 diabetes mellitus (T2DM), and the effects of exercise on HA accumulation, muscle stiffness, strength, ankle joint mobility, and physical function.
HA accumulation will be assessed non- invasively using magnetic resonance imaging.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This single-center, longitudinal design study uses MRI to evaluate the mechanistic effects of exercise on skeletal muscle function.
Twenty-five T2DM patients will be enrolled and be prescribed a 10-week exercise program.
The exercise program will comprise aerobic and resistance components; a moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
MRI data will be acquired at baseline and before and after the intervention that can provide mechanistic insight into the adaptations in lower leg muscle function.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Smita Rao, PhD
- Phone Number: 212-998-9194
- Email: smita.rao@nyu.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Be between the ages of 40 and 75
- Clinical diagnosis of Type 2 diabetes
- Have a BMI less than 40 kg/m2 (due to magnet bore restrictions)
- Able to walk unassisted
Exclusion Criteria:
- Serious cardiac pathology or musculoskeletal problems that would limit exercise ability
- Current open wound or history of plantar ulcer for the last 3 months
- Partial foot amputations
- Inability to ambulate without assistive device
- Stroke or other central nervous system pathology
- Stage 2 hypertension (resting blood pressure >160 systolic or >100 diastolic)
- Contraindications to 3T whole body MRI scanners (e.g., pacemaker, cerebral aneurysm clip, cochlear implant, presence of shrapnel in strategic locations, metal in the eye, claustrophobia, or other problems).
- Subjects with alcoholism, chronic drug use, chronic gastrointestinal disease, or renal or hepatic impairment
- Pregnant women and children
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise Program Group
Participants will be prescribed an individualized 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (ACSM) Guidelines.
|
A 10-week exercise program with both aerobic and resistance components, based on the American College of Sports Medicine (2010), will be individually prescribed to 25 T2DM patients.Exercise training will be performed on Days 1 and 2 of each week under the supervision of licensed physical therapists.
Participants will have the choice of using a treadmill or a recumbent stepper.
The physical therapists will monitor blood glucose level, blood pressure, heart rate, and RPE during each exercise session.
Participants will be asked to exercise at home on Day 3 of each week, and will not be supervised by the study team.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Level of Hyaluronan accumulation in calf muscle of participants
Time Frame: Week 1, Week 11
|
Hyaluronan accumulation (HA) in calf muscle will be assessed using 3D T1ρ and T2-weighted MR scans on a 3T whole-body clinical MRI scanner (Prisma, Siemens Healthcare, Erlangen, Germany) with a 15-channel knee coil (QED, Cleveland OH).
The total scan time is expected to be 29 min, 30 s.
The sequence acquisition parameters will be as follows: TR/TE = 1500 ms/3.78 ms, flip angle = 8°, field of view (FOV) = 140 mm2, spin-lock lengths (TSLs)=0,10ms, 20ms, 30ms, 40ms and 60ms, spin-lock frequency=500Hz matrix size 256 × 128 × 64, slice thickness = 2 m.
|
Week 1, Week 11
|
Change in the Level of Calf muscle stiffness in participants
Time Frame: Week 1, Week 11
|
Calf muscle stiffness will measured using a previously validated device (FDA product classification: non-powered goniometer, 510K exempt).
Briefly, subjects are positioned supine with the knee extended and their leg is secured by Velcro straps.
Torques of 15, 20 and 25 Nm are applied using a hand-held force gauge (FDK 40, Wagner Instruments, Greenwich, CT) and resultant angular kinematics are measured using a digital inclinometer (Checkpoint Inc., Torrance, CA).
Three cycles of testing are performed in ascending order of force application and resultant peak dorsiflexion range of motion is recorded at each force level.
Calf muscle stiffness is calculated as the slope of the resultant curves over the 15 to 25 Nm intervals.
This device has demonstrated high convergent validity compared to motion analysis (Intraclass correlation coefficient (ICC [2,k])> 0.95).
|
Week 1, Week 11
|
Change in the Degree of Passive ankle mobility in participants
Time Frame: Week 1, Week 11
|
Passive ankle mobility will measured using a previously validated device (FDA product classification: non-powered goniometer, 510K exempt).
Briefly, subjects are positioned supine with the knee extended and their leg is secured by Velcro straps.
The axis of rotation of the device is then adjusted in the anteroposterior and supero-inferior directions to approximate the ankle axis of rotation determined by palpation of the distal tips of the medial and lateral malleoli.
Torques of 15, 20 and 25 Nm are applied using a hand-held force gauge (FDK 40, Wagner Instruments, Greenwich, CT) and resultant angular kinematics are measured using a digital inclinometer (Checkpoint Inc., Torrance, CA).
Three cycles of testing are performed in ascending order of force application and resultant peak dorsiflexion range of motion is recorded at each force level.
|
Week 1, Week 11
|
Change in the Level of Calf muscle strength in participants
Time Frame: Week 1, Week 11
|
Calf muscle strength, quantified as peak plantarflexion torque.
An isokinetic dynamometer (Biodex, Shirley, NY) will be used to quantify peak isokinetic torque of the calf muscle at 60 degrees per second in participants' available range of motion (FDA product classification: AC powered dynamometer, 510K exempt).
All participants will be tested in the seated position.
Three practice trials will be given, after which peak plantarflexion torque will be recorded from the highest of three trials.
With these procedures, coefficient of variation of <10% has been reported in individuals with T2DM, indicating good repeatability.
|
Week 1, Week 11
|
Change in the Change in Gait (Stride length) of participants after intervention
Time Frame: Week 1, Week 11
|
The study will use a motion capture system to collect kinematic (marker) and kinetic (force plate and pressure plate) data as subjects walk barefoot at self-selected speed along a 10 m walkway.
A minimum of five successful trials will be collected for each subject.
A trial will be considered successful if the subject made clean force plate contact on the tested side without targeting.
Stride length will be defined as the distance between consecutive initial contacts of the same limb and will be calculated using Visual3D software (C-motion Inc., USA).
|
Week 1, Week 11
|
Change in the Change in Gait (Walking Speed) of participants after intervention
Time Frame: Week 1, Week 11
|
The study will use a motion capture system to collect kinematic (marker) and kinetic (force plate and pressure plate) data as subjects walk barefoot at self-selected speed along a 10 m walkway.
A minimum of five successful trials will be collected for each subject.
A trial will be considered successful if the subject made clean force plate contact on the tested side without targeting.
Walking speed will be defined as distance travelled in unit time and will be calculated using Visual3D software (C-motion Inc., USA).
|
Week 1, Week 11
|
Change in Self-reported physical function of participants after intervention
Time Frame: Week 1, Week 11
|
This will be evaluated using Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function and Pain Interference scales.
PROMIS is a computer adaptive testing outcomes instrument, generated after exhaustive review, and the application of item response theory to calibrate the individual items.
The higher the score indicate higher levels of physical functioning.
All PROMIS measures are scored using the final re-centered item response theory (IRT) item parameters and transformed to the T-score metric (mean=50, SD=10).
|
Week 1, Week 11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Glycemic Control
Time Frame: Week 2, Week 12
|
Glycemic control will be assessed with Hemoglobin A1c test.
Participants will be asked to give 1 mL of blood at baseline and after intervention.
|
Week 2, Week 12
|
Change in the Number of participants with increased physical activity
Time Frame: Week 1, Week 11
|
Physical activity will be assessed using a wrist-worn triaxial accelerometer (Actigraph).
Step counts, and percent of time in sedentary, light and moderate / vigorous physical activity will be quantified for each participant.
The actigraph will be worn for two weeks on the wrist, participants may take it off when bathing and sleeping.
|
Week 1, Week 11
|
Number of Participants who adhere to the Exercise program
Time Frame: Week 12
|
Number of sessions attended will be calculated and used to calculate adherence.
A systematic review of exercise training indicates attrition rates of <20% and adherence rates of >75% in individuals with T2DM.
|
Week 12
|
Number of participants with Neuropathy
Time Frame: Week 1
|
The Michigan Neuropathy Screening Instrument will be used to screen for the presence of peripheral neuropathy.
The Michigan Neuropathy Screening Instrument (MNSI) is used to assess distal symmetrical peripheral neuropathy in diabetes.
It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes
|
Week 1
|
Number of participants with Osteoarthritis
Time Frame: Week 1
|
Presence of knee osteoarthritis may affect levels of serum HA.
American College of Rheumatology (ACR) Clinical Classification Criteria will be used to screen for the presence of knee osteoarthritis.
History and physical examination will be used to screen for knee osteoarthritis using the following criteria: Pain in the knee and three of the following: 1) >50 years of age, 2) Less than 30 minutes of morning stiffness, 3) Crepitus on active motion, 4) Bony tenderness, 5) Bony enlargement, 6) No palpable warmth of synovium.
|
Week 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Smita Rao, PhD, NYU Langone Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Actual)
May 31, 2023
Study Completion (Estimated)
August 31, 2024
Study Registration Dates
First Submitted
May 6, 2020
First Submitted That Met QC Criteria
May 7, 2020
First Posted (Actual)
May 12, 2020
Study Record Updates
Last Update Posted (Estimated)
February 7, 2024
Last Update Submitted That Met QC Criteria
February 6, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-01913
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All of the individual participant data collected during the trial, after deidentification.
IPD Sharing Time Frame
Available after accepted for publication in a peer-reviewed journal.
IPD Sharing Access Criteria
Requests should be directed to smita.rao@nyu.edu.
To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on 10-week exercise program on HA accumulation
-
NYU Langone HealthCompletedPatellar Femoral SyndromeUnited States
-
Region VästerbottenUmeå UniversityUnknown
-
Chinese University of Hong KongCompletedSubacromial Pain SyndromeHong Kong
-
Hamad Medical CorporationHamad Bin Khalifa UniversityUnknown
-
Dalarna UniversitySormland County Council, SwedenCompletedFall Injury | Accidental Fall | Work-related Injury | Work AccidentSweden
-
National University of Ireland, Galway, IrelandUnknownChronic Kidney Diseases | Rheumatoid Arthritis | Cardiovascular Risk Factor | Partner, DomesticIreland
-
Universitaire Ziekenhuizen KU LeuvenVlaamse Federatie voor Sport en Recreatie in de Geestelijke GezondheidszorgCompleted
-
Mercy Medical CenterSusan G. Komen Breast Cancer FoundationCompletedFatigue After Adjuvant Breast Cancer TreatmentUnited States
-
University of PittsburghArthritis FoundationCompletedHypertension | Diabetes | Arthritis | Preventive BehaviorsUnited States